Litcius/Paper detail

VHL suppresses RAPTOR and inhibits mTORC1 signaling in clear cell renal cell carcinoma

Athina Ganner, Christina Gehrke, Marinella Klein, Lena Thegtmeier, Tanja Matulenski, Laura Wingendorf, Lu Wang, Felicitas Pilz, Lars Greidl, Lisa Meid, Fruzsina Kotsis, Gerd Walz, Ian J. Frew, Elke Neumann‐Haefelin

2021Scientific Reports33 citationsDOIOpen Access PDF

Abstract

Inactivation of the tumor suppressor von Hippel-Lindau (VHL) gene is a key event in hereditary and sporadic clear cell renal cell carcinomas (ccRCC). The mechanistic target of rapamycin (mTOR) signaling pathway is a fundamental regulator of cell growth and proliferation, and hyperactivation of mTOR signaling is a common finding in VHL-dependent ccRCC. Deregulation of mTOR signaling correlates with tumor progression and poor outcome in patients with ccRCC. Here, we report that the regulatory-associated protein of mTOR (RAPTOR) is strikingly repressed by VHL. VHL interacts with RAPTOR and increases RAPTOR degradation by ubiquitination, thereby inhibiting mTORC1 signaling. Consistent with hyperactivation of mTORC1 signaling in VHL-deficient ccRCC, we observed that loss of vhl-1 function in C. elegans increased mTORC1 activity, supporting an evolutionary conserved mechanism. Our work reveals important new mechanistic insight into deregulation of mTORC1 signaling in ccRCC and links VHL directly to the control of RAPTOR/mTORC1. This may represent a novel mechanism whereby loss of VHL affects organ integrity and tumor behavior.

Topics & Concepts

mTORC1PI3K/AKT/mTOR pathwayCancer researchBiologyRegulatorClear cell renal cell carcinomaCell growthRPTORSignal transductionCell biologymTORC2SuppressorCancerRenal cell carcinomaMedicineGeneticsInternal medicineGeneRenal cell carcinoma treatmentPI3K/AKT/mTOR signaling in cancerGenetic and Kidney Cyst Diseases